

France

It is estimated that cleaner air in France resulting from the achievement of a '30% internal' rather than a 20% reduction in emissions would result in public health benefits of between €1.2 billion and €3.5 billion per year from 2020.

Annual health benefits include:

- An increase in life expectancy of 16,000 years spread across the population.

- Better health and lower health costs: 1.5 million fewer days of restricted activity; 142,000 fewer days when people need to use respiratory medication; 16,000 fewer consultations for upper respiratory symptoms and asthma.

Other benefits: A more productive workforce - 342,000 fewer working days lost annually due to cardiac and respiratory problems.

Impact assessment, all figures per year	Baseline in 2020	Reduction in EU damage in 2020 compared to the baseline for	
		Cut of 30% with flexibility	-30% internal cut
	Following 20% cut		
Mortality - Life years lost, people aged >29	279,569	7,691	16,042
Deaths in infants (1 to 11 months)	45	1	3
Chronic bronchitis, cases	14,132	337	703
Cardiac and respiratory hospital admissions	7,513	207	432
Restricted activity days (RADs), working age population	24,653,629	716,521	1,494,458
Of which, working days lost	5,423,798	164,083	342,231
Days with respiratory medication use by adults and children	2,518,814	68,073	141,981
Days with lower respiratory symptoms among adults and children	32,706,740	956,706	1,995,416
Consultations for asthma and upper respiratory symptoms	297,220	7,805	16,279

Economic assessment, €millions/year	Benefit from 30% with flexibility cut in GHGs in 2020	Benefit from 30% internal cut in GHGs in 2020
Mortality – lower bound (lower estimate of VOLY applied)	402	838
Mortality – upper bound (upper estimate of VSL applied)	1,492	3,113
Morbidity	176	368
Total, lower bound mortality valuation	578	1,206
Total, upper bound mortality valuation	1,669	3,481